5 completed, 5 recruiting, 3 active not recruiting, 3 terminated. 19 Phase 1, 8 Phase 2.
Follow defactinib: new trials by email Literature Review of defactinib trials Research Report on defactinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Neoadjuvant Avutometinib/Defactinib and mFOLFIRINOX Combination Therapy in Pancreatic Adenocarcinoma Avutometinib (VS-6766) + Defactinib (VS-6063) - Pancreatic Cancer, PDAC - Pancreatic Ductal Adenocarcinoma | Phase 1 / Phase 2 | Not yet recruiting | University of Virginia | 31 | 2026-10-01 | 2026-09-17 |
| Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Pathway Mutant Endometrial Cancer Avutometinib, defactinib, Everolimus - Phase IB, Avutometinib | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 31 | 2026-05-13 | 2026-06-29 |
| A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors VS-7375, Cetuximab, Carboplatin + Pemetrexed + Pembrolizumab - Pancreatic Ductal Adenocarcinoma, Non Small Cell Lung Cancer | Phase 1 / Phase 2 | Recruiting | Verastem, Inc. | 616 | 2025-06-24 | 2026-10-23 |
| 5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours Avutometinib, Defactinib, Temozolomide - Glioblastoma Multiforme (GBM), Glioblastoma Multiform (Grade IV Astrocytoma) | Phase 1 / Phase 2 | Recruiting | Institute of Cancer Research, United Kingdom | 182 | 2024-11-15 | 2026-01-21 |
| Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma Defactinib, Avutometinib, Encorafenib - Cutaneous Melanoma, Brain Metastases | Phase 1 / Phase 2 | Recruiting | University of Utah | 33 | 2024-03-20 | 2025-12-03 |
| Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer avutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxel - KRAS Activating Mutation, Metastatic Cancer | Phase 1 / Phase 2 | Active not recruiting | Verastem, Inc. | 40 | 2023-03-22 | 2025-09-02 |
| Combined Evaluation of Epigenetic and Sensitising Therapy in AML and MDS Decitabine/Cedazuridine 35 Mg-100 Mg ORAL TABLET, Defactinib - Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia | Phase 1 | Recruiting | Clinical Hub for Interventional Research (CHOIR) | 12 | 2022-12-14 | 2026-03-18 |
| Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients avutometinib and sotorasib, avutometinib and sotorasib and defactinib - Non Small Cell Lung Cancer, KRAS Activating Mutation | Phase 1 / Phase 2 | Active not recruiting | Verastem, Inc. | 153 | 2022-04-12 | 2026-01-12 |
| Pembrolizumab + Defactinib In Pleural Mesothelioma Pembrolizumab, Defactinib - Malignant Pleural Mesothelioma | Phase 1 | Withdrawn | Raphael Bueno, MD | 2020-09-01 | 2020-11-17 | |
| ROCKIF Trial: Re-sensitization of Carboplatin-resistant Ovarian Cancer With Kinase Inhibition of FAK VS-6063, Paclitaxel, Carboplatin - Ovarian Cancer | Phase 1 / Phase 2 | Terminated | Michael McHale | 8 | 2018-02-06 | 2026-07-31 |
| Phase I Trial of Defactinib and VS-6766. VS-6766, Defactinib - NSCLC, Low Grade Serous Ovarian Cancer | Phase 1 | Active not recruiting | Institute of Cancer Research, United Kingdom | 87 | 2017-12-12 | 2026-03-10 |
| Study of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Advanced Solid Malignancies (FAK-PD1) Defactinib, Pembrolizumab - Carcinoma, Non-small-cell Lung, Mesothelioma | Phase 1 / Phase 2 | Unknown | NHS Greater Glasgow and Clyde | 59 | 2017-07-04 | 2018-03-19 |
| Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of Defactinib in Combination With Avelumab in Epithelial Ovarian Cancer Part A - VS-6063, Part A - Avelumab - Epithelial Ovarian Cancer | Phase 1 | Terminated | Verastem, Inc. | 98 | 2016-10-01 | 2019-04-30 |
| Defactinib Combined With Pembrolizumab and Gemcitabine in Patients With Advanced Cancer Defactinib, Pembrolizumab, Gemcitabine - Advanced Solid Tumors, Solid Tumors | Phase 1 | Completed | Washington University School of Medicine | 43 | 2016-02-03 | 2021-07-20 |
| A Phase I, Open-label Study of Absorption, Metabolism, and Excretion of Defactinib (VS-6063) in Healthy Male Subjects defactinib - Healthy Subjects | Phase 1 | Completed | Verastem, Inc. | 5 | 2015-08-01 | 2017-01-30 |
| A Phase 1 Dose Escalation Study of VS-5584 Administered in Combination With VS-6063, in Subjects With Relapsed Malignant Mesothelioma VS-5584 and VS-6063 - Relapsed Malignant Mesothelioma | Phase 1 | Terminated | Verastem, Inc. | 21 | 2015-01-01 | 2017-01-30 |
| Phase I Dose Escalation Study of VS-6063 in Japanese Subjects With Non-Hematologic Malignancies Defactinib - Non Hematologic Cancers | Phase 1 | Completed | Verastem, Inc. | 9 | 2013-09-02 | 2017-03-09 |
| Phase I/Ib Study of Paclitaxel in Combination With VS-6063 in Patients With Advanced Ovarian Cancer defactinib, Paclitaxel - Ovarian Cancer | Phase 1 | Completed | Verastem, Inc. | 22 | 2013-02-26 | 2017-05-17 |
| A Study Of PF-04554878 In Patients With Advanced Non-Hematologic Malignancies PF-04554878 - Cancer | Phase 1 | Completed | Verastem, Inc. | 46 | 2008-12-01 | 2017-01-25 |
Pancreatic Neoplasms (6) · Carcinoma, Non-Small-Cell Lung (3) · Mesothelioma, Malignant (2) · Neoplasm Metastasis (2) · Neoplasms (2) · Ovarian Neoplasms (2) · Appendiceal Neoplasms (1) · Biliary Tract Neoplasms (1) · Brain Neoplasms (1) · Carcinoma, Endometrioid (1) · Carcinoma, Ovarian Epithelial (1) · Cholangiocarcinoma (1) · Colorectal Neoplasms (1) · Endometrial Neoplasms (1) · Gastrointestinal Neoplasms (1)
Verastem, Inc. (9) · Institute of Cancer Research, United Kingdom (2) · Clinical Hub for Interventional Research (CHOIR) (1) · M.D. Anderson Cancer Center (1) · Michael McHale (1) · NHS Greater Glasgow and Clyde (1) · Raphael Bueno, MD (1) · University of Utah (1) · University of Virginia (1) · Washington University School of Medicine (1)
United States (13) · United Kingdom (5) · Australia (2) · France (2) · Spain (2) · Belgium (1) · Canada (1) · Japan (1) · Netherlands (1)
Hagop Youssoufian (2) · Hagop Youssoufian, MD (2) · MD Verastem (2) · Christian Ottensmeier (1) · Dean Fennell (1) · Hagop Youssoufian, m (1) · Howard Colman, MD, PhD (1) · Jeff Evans (1) · John Pimanda, Professor (1) · Juanita Lopez, MD, PhD (1) · Kian-Huat Lim, M.D., Ph.D. (1) · Matthew Reilley, MD (1) · Michael McHale (1) · Raphael Bueno, MD (1)
PMID 37598000, PMID 26334219, PMID 40579546, PMID 42814800
2015 (1), 2017 (1)